RenovoRx achieves major milestone with full enrollment in Phase Iii Tiger-Pac trial for locally advanced pancreatic cancer
RNXT•Phase III trial reaches full enrollment
Aug. 11 (Reuters) - RenovoRx Inc. RNXT.O:
- RenovoRx achieves major milestone with full enrollment in Phase III Tiger-Pac trial for locally advanced pancreatic cancer
- RenovoRx - trial completion expected H1 2027; top line data expected H2 2027
